Ibodutant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameIbodutant
Drug Alias Name艾柏度坦Ibodutantum艾波度坦MEN-15596
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 2 receptor antagonists
TargetsNeurokinin 2 receptor
Therapy Area/IndicationsIrritable Bowel Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesMenarini Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesA Menarini Research & Business Service GmbhMenarini GroupRottendorf Pharma Gmbh +[5] 
Active IndicationsN/A
Inactive IndicationsIrritable Bowel Syndrome

Other Information

ATC CodeN/A
Related LinksWikipedia